Medpace Holdings Inc

Medpace Holdings reported second-quarter 2026 earnings of $4.25 per share, up 37.1% year over year, beating the Zacks Consensus Estimate by 4.17%, and raised its full-year revenue guidance to $2.805-$2.885 billion. Net new business awards jumped 28.2% to $795.7 million, driving a net book-to-bill ratio of 1.13, while backlog rose 4.9% to $3.01 billion. The company repurchased approximately 706,000 shares for $294.7 million during the quarter, with $527 million remaining under its buyback authorization. Medpace now expects 2026 earnings between $17.25 and $17.95 per share, above the consensus estimate of $17.51, and management noted oncology accounted for more than half of second-quarter bookings.

Advanced Biomed shares rallied as much as 211% this week, leading a group of biotech gainers that also included Novocure, Medpace, and others. Advanced Biomed, which has not yet commenced commercial sales, soared from $6.71 to an intraday high of $20.87 before closing Thursday at $16.78, up 36.98% on the day. Novocure surged more than 28% after reporting second-quarter total net revenues of $183.6 million, a 16% year-over-year increase, and raising its full-year 2026 revenue guidance to $710 million to $725 million from a prior range of $690 million to $710 million. Medpace gained more than 14% following second-quarter revenue of $707.3 million, up 17.2% from the prior-year period, and a full-year 2026 revenue forecast of $2.805 billion to $2.885 billion. Other notable movers included SciSparc, up over 20% on no specific news, Agenus, up more than 11% after announcing an oversubscribed private placement of up to $340 million, and AgomAb Therapeutics, up more than 11% ahead of expected clinical data readouts.

Medpace Holdings Inc reported second-quarter 2026 revenue of $707.3 million, a 17.2% year-over-year increase, while net new business awards jumped 28.2% to a record $795.7 million. EBITDA rose 17.6% to $153.4 million with a margin of 21.7%, and net income surged 34.5% to $121.4 million, or $4.25 per diluted share. The company ended the quarter with a backlog of approximately $3 billion, up 4.9% from the prior year, and repurchased about 706,000 shares for $294.7 million. For the full year 2026, Medpace guided revenue between $2.805 billion and $2.885 billion, EBITDA of $618 million to $642 million, and earnings per diluted share of $17.25 to $17.95.

Several major companies saw significant after-hours stock moves following their latest quarterly results. Alphabet shares fell more than 4% after the company raised its 2026 capital expenditures forecast to a range of $195 billion to $205 billion, citing artificial intelligence demand, even as second-quarter revenue of $119.8 billion topped expectations. Tesla dropped 3% after adjusted earnings of 33 cents per share missed estimates by 18 cents, despite revenue of $28.24 billion beating forecasts. IBM rose about 2% even though adjusted earnings of $2.93 per share and revenue of $17.16 billion both slightly missed consensus. ServiceNow gained more than 2% after beating estimates with adjusted earnings of 90 cents per share on revenue of $3.99 billion and raising its full-year subscription revenue outlook. Las Vegas Sands lost 6% after adjusted earnings of 59 cents per share and revenue of $3.15 billion fell short of expectations. United Rentals surged 10% after posting adjusted earnings of $12.76 per share on revenue of $4.41 billion, surpassing estimates, and hiking its full-year revenue guidance to a range of $17.5 billion to $17.8 billion. Medpace Holdings soared about 19% after beating second-quarter estimates and raising full-year guidance. Other notable movers included Rollins, which dropped about 10% on weaker-than-expected results, and Shutterstock, which fell 10% after suspending its quarterly dividend.

StockStory highlights Amgen and Medpace as healthcare stocks with sustainable market-beating potential while recommending investors avoid GoodRx. Amgen, with a market cap of $191.1 billion, posted 12.3% annual revenue growth over two years on a $37.22 billion base and generates strong free cash flow. Medpace, valued at $13.57 billion, achieved 16.9% organic revenue growth and expanded its free cash flow margin by 8.3 percentage points over five years. GoodRx, in contrast, saw flat sales and negative returns on capital, with a revenue base of $787.9 million that lacks scale. Amgen trades at $346.68 per share, Medpace at $513.06, and GoodRx at $2.76.

Turtle Creek Asset Management added Medpace Holdings to its Turtle Creek Equity Fund portfolio during the first quarter of 2026. The fund, which finished the quarter with 30 holdings, returned negative 4.8 percent amid heightened market volatility and momentum in AI-related trades. Medpace is a global clinical contract research organization that focuses on small and mid-sized biopharma companies with a full-service offering, distinguishing it from peers that primarily serve Big Pharma. The firm highlighted Medpace's founder-run model, high growth, significant cash flow generation, and opportunistic share repurchases, noting the company bought back just under 10 percent of its outstanding shares last year. Medpace reported first-quarter 2026 revenue of 706.6 million dollars, a 26.5 percent year-over-year increase, and its stock closed at 475.07 dollars per share on June 17, 2026, with a market capitalization of about 13.05 billion dollars.